Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

(Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated ...

Ahmedabad (Gujarat) [India], October 19: Accord Healthcare Limited (Accord) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ... in ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

Africa must boost local vaccine manufacturing to beat mpox and ensure long-term health security, say public health leaders.

The seizure of two containers last October, loaded with counterfeit jerseys allegedly representing major Tanzanian football ...

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

The global periodontal disease treatment market is projected to reach USD 3.63 billion by 2030 from USD 2.58 billion in 2024, ...

Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...